Dengue Fever (DF), Dengue Haemorregic Fever (DHF) and Dengue Shock Syndrome (DSS)
Conditions
Interventions
The study will be carried out in Dhaka Medical College Hospital (DMCH). In total 100 Dengue Haemorrhagic Fever (DHF) and/or Dengue Shock Syndrome (DSS) patients will be enrolled and subsequently assig
Sponsors
Incepta Pharmaceuticals Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: a. Age: More than 15 years and less than 65 years b. NS1 positivity within 4 days and or /(IgM or IgG) positive after 7 days c. Platelet count: below 1,00,000/mm3
Exclusion criteria
Exclusion criteria: a. Known Pregnancy. b. Thrombocytopenia caused by other factor such as Severe Aplastic Anemia (SAA), Chronic Liver Disease (CLD) and Immune- thrombocytopenia (ITP). c. ALT/AST levels higher than 5 times of upper normal limit. d. History of portal vein thrombosis. e. Patients infected with HCV, HBV, chronic liver disease (Drug induced, alcohol induced). f. Patients with any history of receiving immunosuppressive therapy. g. Patients with any severe co-morbidity.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients considered recovered (i.e platelet count above 150×109/L) [Day 4 – 7] Mean platelet count [ Day 0 - 7] | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the safety of Eltrombopag in dengue infected patients will constitute the secondary outcome. Serum SGPT/SGOT lower or equal at Day 5 in comparison to initial values at Day 0 will be considered as safe. [Day 0 and 5. .] Ultra-sonogram (USG) will be performed at day 4 to assess the portal vein thrombosis of the treated patients. No sign of portal vein thrombosis will be considered as safe. [ Day 4] | — |
Countries
Bangladesh
Contacts
Public ContactDr. Ahmedul Kabir
Professor
Outcome results
None listed